<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">oncotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский онкологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian journal of oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-4861</issn><issn pub-type="epub">2312-3168</issn><publisher><publisher-name>Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21294/1814-4861-2021-20-5-115-122</article-id><article-id custom-type="elpub" pub-id-type="custom">oncotomsk-1925</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПЭТ/КТ В ДИАГНОСТИКЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ</article-title><trans-title-group xml:lang="en"><trans-title>MODERN OPPORTUNITIES OF PET/CT IN THE DIAGNOSIS OF PROSTATE CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4369-2057</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вязьмин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vyazmin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры онкологии и лучевой терапии с курсом ПО, 660022, г. Красноярск, ул. Партизана Железняка;</p><p>врач-радиолог отделения радионуклидной диагностики, 660133, г. Красноярск, ул. 1-ая Смоленская, 16 </p><p> </p></bio><bio xml:lang="en"><p>Postgraduate, Department of Oncology and Radiation Therapy with Course of Postgraduate Education, 1, Partizana Zheleznyaka Street, 660022-Krasnoyarsk;</p><p>MD, Nuclear Medicine Radiologist, 16, 1-st Smolenskaya Street, 660133-Krasnoyarsk</p></bio><email xlink:type="simple">gonner@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7210-3020</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зуков</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zukov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой онкологии и лучевой терапиис курсом ПО, </p><p>660022, г. Красноярск, ул. Партизана Железняка</p></bio><bio xml:lang="en"><p>MD, Professor, Head of the Department of Oncology and Radiation Therapy, </p><p>1, Partizana Zheleznyaka Street, 660022-Krasnoyarsk;</p><p>16, 1-st Smolenskaya Street, 660133-Krasnoyarsk</p></bio><email xlink:type="simple">zukov_rus@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7079-4067</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чанчикова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chanchikova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный внештатный специалист-радиолог Минздрава Красноярского края, директор Центра,</p><p>660133, г. Красноярск, ул. 1-ая Смоленская, 16/11</p></bio><bio xml:lang="en"><p>MD, Director of the Center,</p><p>16/11, 1-st Smolenskaya Street, 660133-Krasnoyarsk</p></bio><email xlink:type="simple">chanchikova_ng@skc-fmba.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левченко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Levchenko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>клинический ординатор кафедры онкологии и лучевой терапии с курсом ПО, </p><p>660022, г. Красноярск, ул. Партизана Железняка</p></bio><bio xml:lang="en"><p>Resident Physician, Department of Oncology and Radiation Therapy with Course of Postgraduate Education,</p><p>1, Partizana Zheleznyaka Street, 660022-Krasnoyarsk</p></bio><email xlink:type="simple">kalciferlagerta@gmail.com</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5524-9546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заместитель директора по научной работе и инновационнойдеятельности, заведующий отделением радионуклидной диагностики, 634009, г. Томск, пер. Кооперативный, 54;</p><p>ведущий научный сотрудник НИЦ «Онкотераностика», ИШХБМТ, 634050, Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>MD, DSc, Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department, 5, Kooperativny Street, 634009-Tomsk;</p><p>Leading Researcher of Research Centrum for Oncotheranostics, 30, Lenin Av., Tomsk, 634050</p></bio><email xlink:type="simple">chernov@tnimc.ru</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России;&#13;
КГБУЗ «Красноярский краевой клинический онкологический диспансер им. А.И. Крыжановского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky;&#13;
Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky;&#13;
Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Центр ядерной медицины ФГБУ ФСНКЦ ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>The Center of Nuclear Medicine of the Siberian Research Clinical Centre, FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук;&#13;
Национальный исследовательский Томский политехнический университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science;&#13;
National Research Tomsk Polytechnic University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>29</day><month>10</month><year>2021</year></pub-date><volume>20</volume><issue>5</issue><fpage>115</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вязьмин В.В., Зуков Р.А., Чанчикова Н.Г., Левченко Е.А., Чернов В.И., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Вязьмин В.В., Зуков Р.А., Чанчикова Н.Г., Левченко Е.А., Чернов В.И.</copyright-holder><copyright-holder xml:lang="en">Vyazmin V.V., Zukov R.A., Chanchikova N.G., Levchenko E.A., Chernov V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.siboncoj.ru/jour/article/view/1925">https://www.siboncoj.ru/jour/article/view/1925</self-uri><abstract><p>Цель исследования – представить современные данные о возможностях позитронной эмиссионной компьютерной томографии, совмещенной с компьютерной томографией (ПЭТ/КТ) в диагностике, стадировании и оценке эффективности лечения рака предстательной железы (РПЖ).</p><sec><title>Материал и методы</title><p>Материал и методы. Проведены поиск и анализ крупнейших отечественных и англоязычных баз данных (Elibrary, PubMed, Elsevier и др.) по данной проблеме. Найдено 37 источников, посвященных изучению результатов клинических исследований диагностических возможностей ПЭТ/КТ с различными радиофармацевтическими лекарственными препаратами (РФЛП). Результаты. В обзоре представлены данные о возможностях ПЭТ/КТ с различными РФЛП в диагностике первичной опухоли предстательной железы, визуализации лимфогенных и отдаленных метастазов, а также в оценке эффективности лечения.</p></sec><sec><title>Заключение</title><p>Заключение. Проведенный обзор литературы показал, что применение ПЭТ/КТ при РПЖ во многом зависит от выбранного РФЛП. При этом именно ПЭТ/КТ с РФЛП, основанными на простатическом специфическом мембранном антигене (ПСМА), является наиболее перспективным методом обследования пациентов с РПЖ и может быть рекомендован в качестве дополнительного исследования в тех случаях, когда другие методы лучевой диагностики не дают однозначного ответа. Актуальной остается разработка новых и совершенствование уже используемых РФЛП, которые позволят повысить чувствительность, специфичность и точность диагностики, стадирования, мониторинга и прогноза лечения РПЖ. </p></sec></abstract><trans-abstract xml:lang="en"><p>The purpose is to present a modern data on the possibilities of positron emission computed tomography combined with computed tomography (PET/CT) in the diagnosis, staging and monitoring of prostate cancer (PC).</p><sec><title>Material and Methods</title><p>Material and Methods. A search and analysis of the largest domestic and English-language databases (Elibrary, PubMed, Elsevier, etc.) on this problem was carried out. 37 sources were found devoted to studying the results of clinical trials of the diagnostic capabilities of PET/CT with various radiopharmaceuticals.</p></sec><sec><title>Results</title><p>Results. The presented data on the possibilities of PET/CT with various radiopharmaceuticals in the diagnosis of primary prostate cancer, imaging of lymphogenous and distant metastases, as well as in assessing the effectiveness of treatment.</p></sec><sec><title>Conclusion</title><p>Conclusion. This review of the literature showed that the use of PET/CT in prostate cancer largely depends on the chosen radiopharmaceutical. Moreover, it is PET/CT with PSMA-based radiopharmaceuticals that is the most promising method for examining patients with prostate cancer and can be recommended as an additional study in cases where other methods of radiation diagnostics do not give an unambiguous answer. The development of new and improving the already used radiopharmaceuticals, which will increase the sensitivity, specificity and accuracy of the diagnosis, staging, monitoring and prognosis of treatment of prostate cancer, remains relevant.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>позитронная эмиссионная компьютерная томография</kwd><kwd>рак предстательной железы</kwd><kwd>первичная диагностика</kwd><kwd>метастазы</kwd><kwd>ответ на лечение</kwd><kwd>псмА</kwd></kwd-group><kwd-group xml:lang="en"><kwd>positron emission computed tomography</kwd><kwd>prostate cancer</kwd><kwd>primary diagnosis</kwd><kwd>metastases</kwd><kwd>response to treatment</kwd><kwd>PSMA</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке проекта 075-15-2019-1925 Министерства науки и высшего образования РФ. Постановление Правительства РФ 220.2019.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. 250.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinskii V.V., Petrova G.V. Cancer incidence in Russia in 2018 (morbidity and mortality). Moscow, 2019. 250 р. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Turpin A., Girard E., Baillet C., Pasquier D., Olivier J., Villers A., Puech P., Penel N. Imaging for Metastasis in Prostate Cancer: A Review of the Literature. Front Oncol. 2020 Jan 31; 10: 55. doi: 10.3389/fonc.2020.00055.</mixed-citation><mixed-citation xml:lang="en">Turpin A., Girard E., Baillet C., Pasquier D., Olivier J., Villers A., Puech P., Penel N. Imaging for Metastasis in Prostate Cancer: A Review of the Literature. Front Oncol. 2020 Jan 31; 10: 55. doi: 10.3389/fonc.2020.00055.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lopes P.M., Sepúlveda L., Ramos R., Sousa P. The role of transrectal ultrasound in the diagnosis of prostate cancer: new contributions. Radiol Bras. 2015 Jan-Feb; 48(1): 7–11. doi: 10.1590/0100-3984.2013.0010.</mixed-citation><mixed-citation xml:lang="en">Lopes P.M., Sepúlveda L., Ramos R., Sousa P. The role of transrectal ultrasound in the diagnosis of prostate cancer: new contributions. Radiol Bras. 2015 Jan-Feb; 48(1): 7–11. doi: 10.1590/0100-3984.2013.0010.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tangel M.R., Rastinehad A.R. Advances in prostate cancer imaging. F1000Res. 2018; 7: F1000 Faculty Rev-1337. doi: 10.12688/f1000research.14498.1.</mixed-citation><mixed-citation xml:lang="en">Tangel M.R., Rastinehad A.R. Advances in prostate cancer imaging. F1000Res. 2018; 7: F1000 Faculty Rev-1337. doi: 10.12688/f1000research.14498.1.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed H.U., El-Shater Bosaily A., Brown L.C., Gabe R., Kaplan R., Parmar M.K., Collaco-Moraes Y., Ward K., Hindley R.G., Freeman A., Kirkham A.P., Oldroyd R., Parker C., Emberton M.; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25; 389(10071): 815–822. doi: 10.1016/S0140-6736(16)32401-1.</mixed-citation><mixed-citation xml:lang="en">Ahmed H.U., El-Shater Bosaily A., Brown L.C., Gabe R., Kaplan R., Parmar M.K., Collaco-Moraes Y., Ward K., Hindley R.G., Freeman A., Kirkham A.P., Oldroyd R., Parker C., Emberton M.; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25; 389(10071): 815–822. doi: 10.1016/S0140-6736(16)32401-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sarkar S., Das S. A Review of Imaging Methods for Prostate Cancer Detection. Biomed Eng Comput Biol. 2016 Mar 2; 7(Suppl 1): 1–15. doi: 10.4137/BECB.S34255.</mixed-citation><mixed-citation xml:lang="en">Sarkar S., Das S. A Review of Imaging Methods for Prostate Cancer Detection. Biomed Eng Comput Biol. 2016 Mar 2; 7(Suppl 1): 1–15. doi: 10.4137/BECB.S34255.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Коссов Ф.А., Камолов Б.Ш., Абдуллин И.И., Баранова Е.О., Шориков М.А., Панов В.О., Тюрин И.Е., Матвеев В.Б., Григорьев Н.А., Долгушин Б.И. Применение МРТ/УЗИ fusion-биопсии в диагностике клинически значимого рака предстательной железы. Онкоурология. 2017; 13(3): 61–70. doi: 10.17650/1726-9776-2017-13-3-61-70.</mixed-citation><mixed-citation xml:lang="en">Kossov P.A., Kamolov B.S., Abdullin I.I., Baranova E.O., Shorikov M.A., Panov V.O., Turin I.E., Matveev V.B., Grigor’ev N.A., Dolgushin B.I. The use of MRI/ultrasound fusion biopsy in the diagnosis of clinically significant prostate cancer. Cancer Urology. 2017; 13(3): 61–70. (in Russian). doi: 10.17650/1726-9776-2017-13-3-61-70.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">National Comprehensive Cancer Network [Internet]. URL: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (cited 09.04.2020).</mixed-citation><mixed-citation xml:lang="en">National Comprehensive Cancer Network [Internet]. URL: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (cited 09.04.2020).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Чойнзонов Е.Л. Ядерная медицина в диагностике и адресной терапии злокачественных новообразований. Бюллетень сибирской медицины. 2018; 17(1): 220–231. doi: 10.20538/1682-0363-2018-1-220-231.</mixed-citation><mixed-citation xml:lang="en">Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zelchan R.V., Bragina O.D., Choynzonov E.L. Nuclear medicine as a tool for diagnosis and targeted cancer therapy. Bulletin of Siberian Medicine. 2018; 17(1): 220–231. (in Russian). doi: 10.20538/1682-0363-2018-1-220-231.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Глушков Е.А., Кисличенко А.Г., Рамазанова М.С. Эффективность ОФЭКТ/КТ в обнаружении костных метастазов при раке молочной железы и простаты. Сибирский онкологический журнал. 2015; (6): 19–25.</mixed-citation><mixed-citation xml:lang="en">Glushkov E.A., Kislichenko A.G., Ramazanova M.S. The diagnostic efficacy of SPECT/CT in detection of bone metastasis in patients with breast and prostatic cancer. Siberian Journal of Oncology. 2015; (6): 19–25. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shen B., Huang T., Sun Y., Jin Z., Li X.F. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: «systems molecular imaging» of glucose metabolism. Oncotarget. 2017 Jun 27; 8(26): 43536–43542. doi: 10.18632/oncotarget.16647.</mixed-citation><mixed-citation xml:lang="en">Shen B., Huang T., Sun Y., Jin Z., Li X.F. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: «systems molecular imaging» of glucose metabolism. Oncotarget. 2017 Jun 27; 8(26): 43536–43542. doi: 10.18632/oncotarget.16647.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shen G., Liu J., Jiang X., Li F., Zeng H., Huang R., Kuang A. 18F-FDG PET/CT is still a useful tool in detection of metastatic extent in patients with high risk prostate cancer. Int J Clin Exp Med 2018; 11 (7): 6905–6913.</mixed-citation><mixed-citation xml:lang="en">Shen G., Liu J., Jiang X., Li F., Zeng H., Huang R., Kuang A. 18F-FDG PET/CT is still a useful tool in detection of metastatic extent in patients with high risk prostate cancer. Int J Clin Exp Med 2018; 11 (7): 6905–6913.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shiiba M., Ishihara K., Kimura G., Kuwako T., Yoshihara H., Sato H., Kondo Y., Tsuchiya S., Kumita S. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012 Feb; 26(2): 138–45. doi: 10.1007/s12149-011-0551-6.</mixed-citation><mixed-citation xml:lang="en">Shiiba M., Ishihara K., Kimura G., Kuwako T., Yoshihara H., Sato H., Kondo Y., Tsuchiya S., Kumita S. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012 Feb; 26(2): 138–45. doi: 10.1007/s12149-011-0551-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Jadvar H. Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 Nov; 46(6): 502–506. doi: 10.1053/j.semnuclmed.2016.07.004.</mixed-citation><mixed-citation xml:lang="en">Jadvar H. Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med. 2016 Nov; 46(6): 502–506. doi: 10.1053/j.semnuclmed.2016.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Inoue T. Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey. Asia Ocean J Nucl Med Biol. 2014; 2(1): 19–23.</mixed-citation><mixed-citation xml:lang="en">Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Inoue T. Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey. Asia Ocean J Nucl Med Biol. 2014; 2(1): 19–23.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1(0 1): S5–10. doi: 10.1007/s00259-013-2361-7.</mixed-citation><mixed-citation xml:lang="en">Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013 Jul; 40 Suppl 1(0 1): S5–10. doi: 10.1007/s00259-013-2361-7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Apolo A.B., Pandit-Taskar N., Morris M.J. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. J Nucl Med. 2008 Dec; 49 (12): 2031–2041. doi: 10.2967/jnumed.108.050658.</mixed-citation><mixed-citation xml:lang="en">Apolo A.B., Pandit-Taskar N., Morris M.J. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer. J Nucl Med. 2008 Dec; 49 (12): 2031–2041. doi: 10.2967/jnumed.108.050658.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Farsad M., Schiavina R., Castellucci P., Nanni C., Corti B., Martorana G., Canini R., Grigioni W., Boschi S., Marengo M., Pettinato C., Salizzoni E., Monetti N., Franchi R., Fanti S. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005 Oct; 46(10): 1642–9.</mixed-citation><mixed-citation xml:lang="en">Farsad M., Schiavina R., Castellucci P., Nanni C., Corti B., Martorana G., Canini R., Grigioni W., Boschi S., Marengo M., Pettinato C., Salizzoni E., Monetti N., Franchi R., Fanti S. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005 Oct; 46(10): 1642–9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Souvatzoglou M., Weirich G., Schwarzenboeck S., Maurer T., Schuster T., Bundschuh R.A., Eiber M., Herrmann K., Kuebler H., Wester H.J., Hoefler H., Gschwend J., Schwaiger M., Treiber U., Krause B.J. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011 Jun 1; 17(11): 3751–9. doi: 10.1158/1078-0432.CCR-10-2093.</mixed-citation><mixed-citation xml:lang="en">Souvatzoglou M., Weirich G., Schwarzenboeck S., Maurer T., Schuster T., Bundschuh R.A., Eiber M., Herrmann K., Kuebler H., Wester H.J., Hoefler H., Gschwend J., Schwaiger M., Treiber U., Krause B.J. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011 Jun 1; 17(11): 3751–9. doi: 10.1158/1078-0432.CCR-10-2093.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010 Mar; 254(3): 925–33. doi: 10.1148/radiol.09090413.</mixed-citation><mixed-citation xml:lang="en">Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010 Mar; 254(3): 925–33. doi: 10.1148/radiol.09090413.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schiavina R., Scattoni V., Castellucci P., Picchio M., Corti B., Briganti A., Franceschelli A., Sanguedolce F., Bertaccini A., Farsad M., Giovacchini G., Fanti S., Grigioni W.F., Fazio F., Montorsi F., Rigatti P., Martorana G. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008 Aug; 54(2): 392–401. doi: 10.1016/j.eururo.2008.04.030.</mixed-citation><mixed-citation xml:lang="en">Schiavina R., Scattoni V., Castellucci P., Picchio M., Corti B., Briganti A., Franceschelli A., Sanguedolce F., Bertaccini A., Farsad M., Giovacchini G., Fanti S., Grigioni W.F., Fazio F., Montorsi F., Rigatti P., Martorana G. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008 Aug; 54(2): 392–401. doi: 10.1016/j.eururo.2008.04.030.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wondergem M., van der Zant F.M., van der Ploeg T., Knol R.J. A literature review of 18F-fluoride PET/CT and 18F-choline or 11Ccholine PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34(10): 935–45. doi: 10.1097/MNM.0b013e328364918a.</mixed-citation><mixed-citation xml:lang="en">Wondergem M., van der Zant F.M., van der Ploeg T., Knol R.J. A literature review of 18F-fluoride PET/CT and 18F-choline or 11Ccholine PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun. 2013; 34(10): 935–45. doi: 10.1097/MNM.0b013e328364918a.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Beheshti M., Rezaee A., Geinitz H., Loidl W., Pirich C., Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med. 2016 Oct; 57(Suppl 3): 55S–60S. doi: 10.2967/jnumed.115.169730.</mixed-citation><mixed-citation xml:lang="en">Beheshti M., Rezaee A., Geinitz H., Loidl W., Pirich C., Langsteger W. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med. 2016 Oct; 57(Suppl 3): 55S–60S. doi: 10.2967/jnumed.115.169730.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Асланиди И.П.,Пурсанова Д.М.,Мухортова О.В.,Сильченков А.В., Рощин Д.А., Корякин А.В., Иванов С.А., Широкорад В.И. ПЭТ/КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология. 2015; 11(3): 79–86. doi: 10.17650/1726-9776-2015-11-3-79-86.</mixed-citation><mixed-citation xml:lang="en">Aslanidis I.P., Pursanova D.M., Mukhortova O.V., Silchenkov A.V., Roshin D.A., Koryakin A.V., Ivanov S.A., Shirokorad V.I. 11C–Choline PET/CT in the detection of prostate cancer relapse in patients with rising PSA. Cancer Urology. 2015; 11(3): 79–86. (in Russian). doi: 10.17650/1726-9776-2015-11-3-79-86.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Giovacchini G.,Picchio M.,Coradeschi E.,Bettinardi V.,Gianolli L., Scattoni V., Cozzarini C., Di Muzio N., Rigatti P., Fazio F., Messa C. Predictive factors of [(11)C] choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010 Feb; 37 (2): 301–9. doi: 10.1007/s00259-009-1253-3.</mixed-citation><mixed-citation xml:lang="en">Giovacchini G.,Picchio M.,Coradeschi E.,Bettinardi V.,Gianolli L., Scattoni V., Cozzarini C., Di Muzio N., Rigatti P., Fazio F., Messa C. Predictive factors of [(11)C] choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010 Feb; 37 (2): 301–9. doi: 10.1007/s00259-009-1253-3.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Treglia G., Ceriani L., Sadeghi R., Giovacchini G., Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014 May; 52(5): 725–33. doi: 10.1515/cclm-2013-0675.</mixed-citation><mixed-citation xml:lang="en">Treglia G., Ceriani L., Sadeghi R., Giovacchini G., Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med. 2014 May; 52(5): 725–33. doi: 10.1515/cclm-2013-0675.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Fuccio C., Schiavina R., Castellucci P., Rubello D., Martorana G., Celli M., Malizia C., Profitos M.B., Marzola M.C., Pettinato V., Fanti S. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011; 38(11): 1985–9. doi: 10.1007/s00259-011-1867-0.</mixed-citation><mixed-citation xml:lang="en">Fuccio C., Schiavina R., Castellucci P., Rubello D., Martorana G., Celli M., Malizia C., Profitos M.B., Marzola M.C., Pettinato V., Fanti S. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011; 38(11): 1985–9. doi: 10.1007/s00259-011-1867-0.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Брагина О.Д., Чернов В.И., Ларькина М.С., Зельчан Р.В., Синилкин И.Г., Медведева А.А. Простатический специфический мембранный антиген: современные возможности в диагностике рака предстательной железы Молекулярная медицина. 2018; 16(4): 3–8. doi: 10.29296/24999490-2018-04-01.</mixed-citation><mixed-citation xml:lang="en">Bragina O.D., Chernov V.I., Larkina M.S., Zelchan R.V., Sinilkin I.G., Medvedeva A.A. Prostate specific membrane antigen: current possibilities in the diagnosis of prostate cancer. Molecular Medicine. 2018; 16 (4): 3–8. (in Russian)]. doi: 10.29296/24999490-2018-04-01.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., Holland-Letz T., Hadaschik B.A., Giesel F.L., Debus J., Haberkorn U. Comparison of PET imaging with a (68)Galabelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan; 41(1): 11–20. doi: 10.1007/s00259-013-2525-5.</mixed-citation><mixed-citation xml:lang="en">Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., Holland-Letz T., Hadaschik B.A., Giesel F.L., Debus J., Haberkorn U. Comparison of PET imaging with a (68)Galabelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan; 41(1): 11–20. doi: 10.1007/s00259-013-2525-5.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Maurer T., Gschwend J.E., Rauscher I., Souvatzoglou M., Haller B., Weirich G., Wester H.J., Heck M., Kübler H., Beer A.J., Schwaiger M., Eiber M. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016 May; 195(5): 1436–1443. doi: 10.1016/j.juro.2015.12.025.</mixed-citation><mixed-citation xml:lang="en">Maurer T., Gschwend J.E., Rauscher I., Souvatzoglou M., Haller B., Weirich G., Wester H.J., Heck M., Kübler H., Beer A.J., Schwaiger M., Eiber M. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016 May; 195(5): 1436–1443. doi: 10.1016/j.juro.2015.12.025.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mottet N., Bellmunt J., Bolla M., Briers E., Cumberbatch M.G., De Santis M., Fossati N., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., Matveev V.B., Moldovan P.C., van den Bergh R.C.N., Van den Broeck T., van der Poel H.G., van der Kwast T.H., Rouvière O., Schoots I.G., Wiegel T., Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr; 71(4): 618–629. doi: 10.1016/j.eururo.2016.08.003.</mixed-citation><mixed-citation xml:lang="en">Mottet N., Bellmunt J., Bolla M., Briers E., Cumberbatch M.G., De Santis M., Fossati N., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., Matveev V.B., Moldovan P.C., van den Bergh R.C.N., Van den Broeck T., van der Poel H.G., van der Kwast T.H., Rouvière O., Schoots I.G., Wiegel T., Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr; 71(4): 618–629. doi: 10.1016/j.eururo.2016.08.003.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Afshar-Oromieh A., Debus N., Uhrig M., Hope T.A., Evans M.J., Holland-Letz T., Giesel F.L., Kopka K., Hadaschik B., Kratochwil C., Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Nov; 45(12): 2045–2054. doi: 10.1007/s00259-018-4079-z.</mixed-citation><mixed-citation xml:lang="en">Afshar-Oromieh A., Debus N., Uhrig M., Hope T.A., Evans M.J., Holland-Letz T., Giesel F.L., Kopka K., Hadaschik B., Kratochwil C., Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Nov; 45(12): 2045–2054. doi: 10.1007/s00259-018-4079-z.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Meller B., Bremmer F., Sahlmann C.O., Hijazi S., Bouter C., Trojan L., Meller J., Thelen P. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015 Dec; 5(1): 66. doi: 10.1186/s13550-015-0145-8.</mixed-citation><mixed-citation xml:lang="en">Meller B., Bremmer F., Sahlmann C.O., Hijazi S., Bouter C., Trojan L., Meller J., Thelen P. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015 Dec; 5(1): 66. doi: 10.1186/s13550-015-0145-8.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ettala O., Malaspina S., Tuokkola T., Luoto P., Löyttyniemi E., Boström P.J., Kemppainen J. Prospective study on the effect of shortterm androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Mar; 47(3): 665–673. doi: 10.1007/s00259-019-04635-7.</mixed-citation><mixed-citation xml:lang="en">Ettala O., Malaspina S., Tuokkola T., Luoto P., Löyttyniemi E., Boström P.J., Kemppainen J. Prospective study on the effect of shortterm androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Mar; 47(3): 665–673. doi: 10.1007/s00259-019-04635-7.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C., Liu T., Zhang Z., Zhang N., Du P., Yang Y., Liu Y., Yu W., Li N., Gorin M.A., Rowe S.P., Zhu H., Yan K., Yang Z. 68Ga-PSMA PET/ CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. J Nucl Med. 2020 Sep; 61(9): 1314–1319. doi: 10.2967/jnumed.119.235333.</mixed-citation><mixed-citation xml:lang="en">Liu C., Liu T., Zhang Z., Zhang N., Du P., Yang Y., Liu Y., Yu W., Li N., Gorin M.A., Rowe S.P., Zhu H., Yan K., Yang Z. 68Ga-PSMA PET/ CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results. J Nucl Med. 2020 Sep; 61(9): 1314–1319. doi: 10.2967/jnumed.119.235333.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Bouchelouche K., Choyke P.L. Advances in prostate-specific membrane antigen PET of prostate cancer. Curr Opin Oncol. 2018 May; 30(3): 189–196. doi: 10.1097/CCO.0000000000000439.</mixed-citation><mixed-citation xml:lang="en">Bouchelouche K., Choyke P.L. Advances in prostate-specific membrane antigen PET of prostate cancer. Curr Opin Oncol. 2018 May; 30(3): 189–196. doi: 10.1097/CCO.0000000000000439.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zaman M.U., Fatima N., Zaman A., Sajid M., Zaman U., Zaman S. Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer? Asian Pac J Cancer Prev. 2017 Oct 26; 18(10): 2625–2628. doi: 10.22034/APJCP.2017.18.10.2625.</mixed-citation><mixed-citation xml:lang="en">Zaman M.U., Fatima N., Zaman A., Sajid M., Zaman U., Zaman S. Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer? Asian Pac J Cancer Prev. 2017 Oct 26; 18(10): 2625–2628. doi: 10.22034/APJCP.2017.18.10.2625.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
